BR112018008965A8 - terapia de reposição de plasminogênio para deficiência de plasminogênio - Google Patents

terapia de reposição de plasminogênio para deficiência de plasminogênio

Info

Publication number
BR112018008965A8
BR112018008965A8 BR112018008965A BR112018008965A BR112018008965A8 BR 112018008965 A8 BR112018008965 A8 BR 112018008965A8 BR 112018008965 A BR112018008965 A BR 112018008965A BR 112018008965 A BR112018008965 A BR 112018008965A BR 112018008965 A8 BR112018008965 A8 BR 112018008965A8
Authority
BR
Brazil
Prior art keywords
plasminogen
deficiency
replacement therapy
subject
deficient subject
Prior art date
Application number
BR112018008965A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018008965A2 (pt
Inventor
Thibaudeau Karen
Robitaille Martin
Laurin Pierre
Plum Stacy
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of BR112018008965A2 publication Critical patent/BR112018008965A2/pt
Publication of BR112018008965A8 publication Critical patent/BR112018008965A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018008965A 2015-11-03 2016-11-03 terapia de reposição de plasminogênio para deficiência de plasminogênio BR112018008965A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (2)

Publication Number Publication Date
BR112018008965A2 BR112018008965A2 (pt) 2018-11-21
BR112018008965A8 true BR112018008965A8 (pt) 2019-02-26

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008965A BR112018008965A8 (pt) 2015-11-03 2016-11-03 terapia de reposição de plasminogênio para deficiência de plasminogênio

Country Status (24)

Country Link
US (1) US11291711B2 (https=)
EP (1) EP3370760B1 (https=)
JP (1) JP6878423B2 (https=)
KR (1) KR102821400B1 (https=)
CN (1) CN108289935A (https=)
AU (1) AU2016347863B2 (https=)
BR (1) BR112018008965A8 (https=)
CA (1) CA3002915C (https=)
DK (1) DK3370760T3 (https=)
ES (1) ES3055824T3 (https=)
FI (1) FI3370760T3 (https=)
IL (1) IL258913B (https=)
LT (1) LT3370760T (https=)
MX (1) MX2018005588A (https=)
MY (1) MY199581A (https=)
PL (1) PL3370760T3 (https=)
PT (1) PT3370760T (https=)
RS (1) RS67519B1 (https=)
RU (1) RU2736831C2 (https=)
SI (1) SI3370760T1 (https=)
SM (1) SMT202500451T1 (https=)
TW (1) TWI801331B (https=)
WO (1) WO2017077380A1 (https=)
ZA (1) ZA201802820B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CA3008185C (en) * 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
TWI624268B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
US20100028321A1 (en) * 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN103221070B (zh) * 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
WO2017101870A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Also Published As

Publication number Publication date
EP3370760A4 (en) 2019-06-26
DK3370760T3 (da) 2025-12-22
ES3055824T3 (en) 2026-02-16
WO2017077380A1 (en) 2017-05-11
KR102821400B1 (ko) 2025-06-18
PT3370760T (pt) 2025-12-03
SI3370760T1 (sl) 2026-02-27
RU2736831C2 (ru) 2020-11-20
SMT202500451T1 (it) 2026-01-12
IL258913A (en) 2018-06-28
US11291711B2 (en) 2022-04-05
MY199581A (en) 2023-11-07
CA3002915C (en) 2024-01-16
TWI801331B (zh) 2023-05-11
CA3002915A1 (en) 2017-05-11
ZA201802820B (en) 2019-07-31
EP3370760B1 (en) 2025-10-01
NZ742657A (en) 2024-04-26
PL3370760T3 (pl) 2026-03-23
JP2018533589A (ja) 2018-11-15
TW201722463A (zh) 2017-07-01
AU2016347863A1 (en) 2018-06-07
AU2016347863B2 (en) 2023-11-09
RS67519B1 (sr) 2025-12-31
LT3370760T (lt) 2025-12-29
BR112018008965A2 (pt) 2018-11-21
RU2018120182A3 (https=) 2020-04-27
JP6878423B2 (ja) 2021-05-26
IL258913B (en) 2021-12-01
KR20180083348A (ko) 2018-07-20
US20190231854A1 (en) 2019-08-01
FI3370760T3 (fi) 2025-12-05
MX2018005588A (es) 2018-11-09
EP3370760A1 (en) 2018-09-12
CN108289935A (zh) 2018-07-17
RU2018120182A (ru) 2019-12-04

Similar Documents

Publication Publication Date Title
BR112018008965A2 (pt) terapia de reposição de plasminogênio para deficiência de plasminogênio
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX377438B (es) Administracion de tasimelteon en condiciones de ayuno.
BR112017008805A2 (pt) tratamento de córnea usando laminina
EA201591055A1 (ru) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
PH12017501334A1 (en) 3,5-diaminopyrazole kinase inhibitors
GB2550750A (en) Anthelmintic compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]